These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27634311)

  • 1. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?
    Atzeni F; Benucci M; Talotta R; Masala IF; Sarzi-Puttini P; Govoni M
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1403-1411. PubMed ID: 27634311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
    Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
    Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis.
    Tanaka Y; Hirata S
    Drugs; 2014 Dec; 74(18):2129-39. PubMed ID: 25389048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
    Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
    BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?
    Fautrel B; Den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):550-65. PubMed ID: 26697766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
    Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
    Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
    Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
    Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Birkner B; Rech J; Stargardt T
    PLoS One; 2020; 15(1):e0226754. PubMed ID: 31895926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis.
    Vinson D; Molet-Benhamou L; Degboé Y; den Broeder A; Ibrahim F; Pontes C; Westhovens R; Závada J; Pham T; Barnetche T; Constantin A; Ruyssen-Witrand A
    Arthritis Res Ther; 2020 Apr; 22(1):97. PubMed ID: 32349791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
    Brahe CH; Krabbe S; Østergaard M; Ørnbjerg L; Glinatsi D; Røgind H; Jensen HS; Hansen A; Nørregaard J; Jacobsen S; Terslev L; Huynh TK; Jensen DV; Manilo N; Asmussen K; Brown Frandsen P; Boesen M; Rastiemadabadi Z; Morsel Carlsen L; Møller JM; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2019 Jan; 58(1):110-119. PubMed ID: 30169706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.
    Subesinghe S; Scott IC
    Expert Rev Clin Pharmacol; 2015; 8(6):751-60. PubMed ID: 26289226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.
    Fautrel B
    Joint Bone Spine; 2018 Dec; 85(6):679-685. PubMed ID: 29452300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.
    Navarro-Millán I; Sattui SE; Curtis JR
    Clin Ther; 2013 Nov; 35(11):1850-61.e1. PubMed ID: 24156821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
    Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
    Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
    Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment reduction in well-controlled rheumatoid arthritis. State of knowledge].
    Krüger K; Edelmann E
    Z Rheumatol; 2015 Jun; 74(5):414-20. PubMed ID: 26085073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.